List of Excipients in Branded Drug MAGNESIUM SULFATE IN WATER

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Hospira Inc	MAGNESIUM SULFATE IN WATER	magnesium sulfate in water	0409-6730	SODIUM HYDROXIDE
Hospira Inc	MAGNESIUM SULFATE IN WATER	magnesium sulfate in water	0409-6730	SULFURIC ACID
Hospira Inc	MAGNESIUM SULFATE IN WATER	magnesium sulfate in water	0409-6730	WATER
A-S Medication Solutions	MAGNESIUM SULFATE IN WATER	magnesium sulfate in water	50090-2376	SODIUM HYDROXIDE

Generic Drugs Containing MAGNESIUM SULFATE IN WATER

Company	Ingredient	NDC	Excipient
B Braun Medical Inc	magnesium sulfate heptahydrate	0264-4204	SODIUM HYDROXIDE
B Braun Medical Inc	magnesium sulfate heptahydrate	0264-4204	SULFURIC ACID
B Braun Medical Inc	magnesium sulfate heptahydrate	0264-4204	WATER
B Braun Medical Inc	magnesium sulfate heptahydrate	0264-4206	SODIUM HYDROXIDE

What are the Most Frequently-Used Excipients in MAGNESIUM SULFATE IN WATER?

# Of NDCs	Excipient
4	SODIUM HYDROXIDE
4	SULFURIC ACID
4	WATER

Last updated: August 10, 2026

Magnesium sulfate in water is a low-complexity, off-patent pharmaceutical platform with demand concentrated in hospital injection, obstetric emergency care, electrolyte replacement, and selected oral products. The strongest commercial opportunities are ready-to-use presentations, preservative-free sterile manufacturing, differentiated concentrations, closed-system packaging, and reliable supply rather than active-ingredient exclusivity. Standard products face limited patent barriers and intense generic competition.

Magnesium Sulfate in Water: Excipient Strategy, Patent Position, and Commercial Opportunities

What is magnesium sulfate in water used for?

Magnesium sulfate in water is an aqueous pharmaceutical preparation in which magnesium sulfate is the active ingredient, not an excipient. The solution may contain only Water for Injection or may include pH-adjusting, tonicity-adjusting, or antimicrobial ingredients depending on the route and presentation.

Injectable magnesium sulfate is used for:

• Magnesium deficiency and hypomagnesemia
• Prevention and treatment of seizures associated with preeclampsia and eclampsia
• Certain acute obstetric protocols
• Selected arrhythmia and electrolyte-management applications
• Hospital compounding and preparation of diluted intravenous solutions

Common commercial strengths include concentrated solutions such as 50% magnesium sulfate and lower-strength presentations such as 20%, 10%, or 4%. The appropriate strength depends on the indication, route, dosing protocol, and need for dilution. Product labeling controls concentration, administration rate, warnings, and compatibility requirements. (DailyMed, 2024a; DailyMed, 2024b)

The commercial distinction is important: a 50% product is usually a concentrate requiring dilution, while a lower-strength product can be positioned as ready-to-use or closer to administration-ready.

What is the formulation and excipient strategy for magnesium sulfate injection?

The core formulation is simple: magnesium sulfate dissolved in Water for Injection. The primary development challenge is not chemical complexity but control of sterility, concentration, container compatibility, particulate matter, stability, and dosing risk.

Typical formulation architecture

Component	Commercial role	Key development issue
Magnesium sulfate heptahydrate or equivalent magnesium sulfate source	Active pharmaceutical ingredient	Assay, identity, water content, impurity profile
Water for Injection	Solvent	Sterility, endotoxin control, conductivity, microbial control
Hydrochloric acid or sodium hydroxide, where used	pH adjustment	Stability and compatibility
Sodium chloride, where included	Tonicity or formulation adjustment	Osmolality and infusion tolerance
Preservative, where included	Multidose antimicrobial protection	Neonatal, obstetric, and intrathecal-use restrictions
Container-closure system	Product protection and delivery	Extractables, leachables, adsorption, seal integrity

The preferred strategy for hospital injectable products is often a minimal-excipient, preservative-free formulation. This reduces toxicological review, avoids preservative restrictions, simplifies labeling, and supports use in sensitive populations.

Why preservative-free products have commercial value

Preservative-free magnesium sulfate can be positioned for:

• Obstetric emergency departments
• Intensive-care units
• Neonatal and pediatric settings
• Pharmacy-controlled sterile preparation
• Single-dose ampoules, vials, syringes, or bags
• Institutional protocols that prohibit multidose preservatives

A preservative-free claim is not itself a patentable commercial moat. Its value comes from manufacturing controls, regulatory compliance, packaging selection, and hospital procurement specifications.

Concentration and osmolality strategy

Highly concentrated magnesium sulfate solutions can be hypertonic and may require dilution before intravenous administration. A product strategy should therefore separate:

1. Concentrated ampoules or vials for pharmacy dilution.
2. Ready-to-use bags for standardized protocols.
3. Intermediate concentrations for reduced preparation time.
4. Small-volume emergency presentations for rapid deployment.

A ready-to-use bag can reduce compounding steps and medication-error exposure. Its commercial value is strongest where hospitals prioritize standardized dose delivery and workflow efficiency. The tradeoff is higher shipping volume, larger packaging, and potentially shorter shelf-life after terminal sterilization or aseptic filling.

What FDA regulatory status applies to magnesium sulfate in water?

Magnesium sulfate injection is generally regulated as a prescription sterile drug product in the United States. The regulatory pathway depends on the product’s dosage form, route, strength, formulation, labeling, and reference-product relationship.

U.S. regulatory considerations

Issue	Commercial implication
Prescription injectable status	Requires drug manufacturing, quality, labeling, and pharmacovigilance controls
Abbreviated New Drug Application pathway	May be available for a qualifying generic product
Sterility and endotoxin controls	Create meaningful manufacturing barriers
Strength and route differences	May require separate regulatory assessment
Ready-to-use packaging	Can create product-specific development and labeling work
Preservative-free presentation	May support differentiation but does not eliminate generic substitution
Container-closure changes	Can trigger stability and extractables/leachables work

The FDA-approved labeling for magnesium sulfate injection identifies the active ingredient, concentration, route, warnings, and dosing instructions. Products are commonly supplied in single-dose vials, ampules, or larger containers. (DailyMed, 2024a; DailyMed, 2024b)

The FDA’s Orange Book should be reviewed by product-specific application number and dosage form. A generic magnesium sulfate injection may have an Orange Book entry without carrying meaningful blocking patents. The presence of a listing does not establish a durable patent barrier.

What patents protect magnesium sulfate in water?

Standard magnesium sulfate in water generally has limited molecule-level patent protection because magnesium sulfate is an established inorganic salt with long-standing medical use. Commercial protection is more likely to arise from formulation, packaging, manufacturing, delivery, or a narrow method of use.

Patent categories with potential relevance

Patent category	Relevance to standard magnesium sulfate injection
Composition-of-matter patent	Low relevance for established magnesium sulfate
Basic aqueous solution patent	Usually limited unless a narrow stability or concentration feature is claimed
Formulation patent	Possible for defined excipient systems, pH ranges, or stability profiles
Container patent	Possible for specialized bags, syringes, or dual-chamber systems
Manufacturing patent	Possible for sterilization, filling, crystallization, or impurity control
Method-of-use patent	Possible for a specific dosing protocol or patient population
Device patent	Possible for premixed infusion systems or dose-delivery technology
Trade secret	Potentially relevant to process controls and yield optimization

A product developer should distinguish patent ownership from practical market protection. A patent on a delivery container may not block a conventional vial. A patent on a narrow dosing method may not prevent sale for hypomagnesemia. A manufacturing patent may be avoidable through a different process.

How strong is the patent estate for magnesium sulfate in water?

The patent estate for conventional magnesium sulfate aqueous products is generally weak at the active-ingredient level and moderate only where the product has a differentiated formulation or delivery system.

The strongest defensible positions are likely to involve:

• A stable high-concentration solution with defined impurity limits
• A ready-to-use premixed infusion bag
• A dual-chamber system that separates magnesium sulfate from an incompatible diluent
• A prefilled syringe with a controlled concentration and safety feature
• A specific low-volume presentation for emergency dosing
• A formulation with a demonstrated shelf-life advantage
• A device-enabled administration system
• A novel combination with another electrolyte or infusion component

Claims should be drafted around measurable product attributes and manufacturing steps. Broad claims covering "magnesium sulfate in water" would face substantial prior-art and enablement risk.

When does magnesium sulfate in water lose exclusivity?

Magnesium sulfate itself has no meaningful modern small-molecule exclusivity period comparable to a newly approved branded pharmaceutical. Standard injectable products are typically exposed to generic competition based on long-established use, public compendial standards, and multiple historical manufacturers.

Exclusivity timeline

Protection type	Expected relevance
New chemical entity exclusivity	Not applicable to established magnesium sulfate
Standard orphan exclusivity	Not generally relevant to conventional magnesium sulfate products
Pediatric exclusivity	Product-specific and not inherent to the active ingredient
New formulation exclusivity	Possible only if supported by an eligible regulatory approval
Method-of-use exclusivity	Possible but narrow and label-dependent
Patent term	Depends on the particular formulation, device, or process patent
Regulatory exclusivity for conventional generic injection	Usually limited compared with novel drugs

The commercial life of a standard product depends more on manufacturing economics, supply reliability, hospital contracts, shortages, and procurement preference than on patent expiry.

Are there Paragraph IV challenges for magnesium sulfate injection?

Paragraph IV litigation is possible when a generic applicant certifies that a listed patent is invalid, unenforceable, or not infringed. For conventional magnesium sulfate injection, the likelihood of high-value Paragraph IV litigation is generally lower than for branded drugs with extensive Orange Book patent estates.

Potential Paragraph IV targets could include:

• A branded ready-to-use infusion bag
• A proprietary container-closure system
• A formulation with an asserted stability advantage
• A protected combination product
• A device-linked presentation
• A narrow method-of-use label

For a basic magnesium sulfate injection, litigation risk is more likely to arise from product quality, manufacturing, supply, or procurement disputes than from a dense patent thicket. Patent counsel should analyze the Orange Book listing for each reference product rather than treating magnesium sulfate as a single legal asset.

What formulation patents could protect magnesium sulfate in water?

Formulation patents could focus on technical parameters that improve clinical handling or product stability.

Potential claim themes

• Defined magnesium sulfate concentration ranges
• Controlled pH ranges
• Low particulate levels
• Reduced discoloration or degradation
• Stabilized solutions for extended storage
• Preservative-free multidose packaging
• Compatibility with polyolefin or cyclic olefin polymer containers
• Reduced extractables and leachables
• Controlled osmolality for direct administration
• Premixed solutions with specified diluents
• Improved low-temperature stability
• Terminally sterilized products with defined shelf-life

A patent position is stronger when the claimed formulation solves a documented technical problem and has comparative data against conventional products. A concentration alone is unlikely to create strong exclusivity if it is predictable from known clinical practice.

How do manufacturing and intellectual-property barriers affect entry?

Manufacturing barriers matter more than active-ingredient patents.

Key technical barriers

Sterile filling

Magnesium sulfate injection requires validated aseptic processing or terminal sterilization, depending on the product design. The manufacturer must control bioburden, endotoxin, container integrity, particulate matter, and fill accuracy.

Concentration control

High-strength solutions require precise weighing, dissolution, sampling, and fill-volume control. Small concentration errors can create clinically significant dosing differences.

Container compatibility

The formulation must be evaluated against glass, polyolefin, elastomer closures, syringes, and infusion bags. Magnesium sulfate solutions can interact with packaging components or other infusion materials.

Stability

Stability programs should evaluate assay, pH, appearance, particulate matter, sterility, endotoxins, container integrity, and degradation products across long-term and accelerated conditions.

Supply-chain resilience

Hospital buyers may favor suppliers with redundant API sources, validated alternate packaging, domestic or regional sterile capacity, and documented shortage-management procedures.

These barriers can support customer retention even when patents are absent.

What commercial opportunities exist for magnesium sulfate in water?

1. Ready-to-use premixed infusion bags

Premixed bags can replace pharmacy dilution of concentrated ampoules. The opportunity is strongest in hospitals with high obstetric volume, standardized eclampsia protocols, and pressure to reduce medication preparation.

Commercial advantages include:

• Reduced preparation time
• Lower dilution-error risk
• Standardized dosing
• Simplified inventory management
• Better compatibility with automated dispensing workflows

The principal disadvantages are higher logistics costs and potentially narrower demand by concentration.

2. Prefilled syringes

A prefilled syringe can target emergency departments, obstetric units, ambulances, and procedural settings. The value proposition depends on dose standardization, labeling clarity, delivery speed, and compatibility with hospital devices.

A syringe product may support device or packaging claims, but the active ingredient remains vulnerable to substitution.

3. Low-volume emergency presentations

Small-volume ampoules or syringes can address emergency administration where rapid access matters more than unit cost. Clear concentration differentiation is essential because magnesium sulfate products may be stocked in multiple strengths.

4. Preservative-free institutional products

A preservative-free product can target neonatal, pediatric, and obstetric customers. It can also simplify institutional protocols that restrict preservatives.

5. Dual-chamber or pharmacy-compounding systems

A dual-chamber system can separate magnesium sulfate from a diluent until administration. This may extend stability or reduce preparation steps. The product would face higher development costs but could support stronger patent and regulatory differentiation.

6. Contract manufacturing and private-label supply

Because the molecule is generic, manufacturers can generate value through:

• Private-label hospital products
• Regional sterile injectables supply
• Emergency-medicine portfolios
• Outsourced hospital pharmacy products
• Government and public-health tenders
• Supply agreements with group purchasing organizations

The major risks are price compression, quality-system costs, and customer concentration.

Which companies are challenging the magnesium sulfate market?

The market is typically fragmented among generic injectable manufacturers, hospital suppliers, contract manufacturers, and regional pharmaceutical companies. Competition is based on:

• FDA approval status
• Product availability
• Concentration range
• Preservative-free status
• Package size
• Sterile manufacturing capacity
• Institutional contracting
• Shortage performance
• Distribution reach

A new entrant is unlikely to win through active-ingredient differentiation. It must compete through supply assurance, packaging, workflow reduction, or a differentiated regulatory product.

What is the revenue exposure and market outlook?

Magnesium sulfate products generally have low unit prices but can generate recurring institutional revenue because demand is protocol-driven and hospitals maintain stock for urgent use.

Revenue exposure is strongest in:

• Obstetric hospitals
• Emergency departments
• Intensive-care units
• Pediatric and neonatal centers
• Government hospitals
• Hospital pharmacy outsourcing
• International markets with limited local sterile manufacturing

The principal commercial risks are generic price erosion, tender-based purchasing, low switching costs, and substitution among concentrations. A manufacturer with only a conventional vial may face limited pricing power. A manufacturer with ready-to-use packaging, dependable supply, and a broader electrolyte portfolio can improve account value.

How does magnesium sulfate compare with competing electrolyte products?

Product	Primary use	Differentiation opportunity	Patent intensity
Magnesium sulfate injection	Magnesium replacement and obstetric seizure prevention	Premix, syringe, concentration, packaging	Low for active ingredient
Potassium chloride injection	Potassium replacement	Premix, lower-concentration safety products, closed systems	Low to moderate by presentation
Calcium gluconate injection	Calcium replacement and emergency use	Ready-to-use presentation, compatibility, packaging	Low for active ingredient
Sodium bicarbonate injection	Acidosis and emergency use	Prefilled syringes, stability, emergency kits	Low to moderate
Balanced electrolyte solutions	Fluid and electrolyte replacement	Bag design, formulation, clinical protocol	Higher at formulation and delivery level

Magnesium sulfate is attractive as part of a hospital electrolyte portfolio. A supplier can use shared sterile infrastructure, distribution, and contracting relationships across multiple products.

What generic launch scenarios exist for magnesium sulfate in water?

Conventional generic launch

A manufacturer launches standard vials or ampoules after establishing an approved generic pathway. This approach has low differentiation and high price pressure.

Workflow-focused launch

The manufacturer launches ready-to-use bags or prefilled syringes. The product competes on preparation reduction and medication safety rather than ingredient price.

Shortage-response launch

A supplier enters when incumbent manufacturers experience shortages or manufacturing interruptions. This can produce rapid institutional demand but requires reliable capacity and regulatory execution.

Regional launch

A manufacturer targets countries or hospital systems with limited sterile injectable competition. Geographic value depends on registration requirements, local procurement rules, and cold-chain or distribution infrastructure.

Portfolio launch

Magnesium sulfate is bundled with calcium, potassium, sodium bicarbonate, and other hospital injectables. The portfolio can improve contracting economics and reduce customer-acquisition costs.

What geographic coverage should a commercial strategy prioritize?

The United States offers a mature generic market with strong demand for sterile injectables but intense price competition and high compliance costs. Europe and other developed markets reward reliable supply, multilingual labeling, and hospital tender performance.

Emerging markets may offer greater pricing flexibility but can require:

• Local registration
• Local manufacturing or supply arrangements
• Pharmacopoeial compliance
• Government tender participation
• Local pharmacovigilance infrastructure
• Country-specific packaging and labeling

The strongest geographic strategy is usually regional rather than global at launch. Sterile products benefit from proximity to customers and reduced distribution complexity.

Key Takeaways

1. Magnesium sulfate in water is an established active pharmaceutical ingredient, not an excipient-led innovation platform.
2. Conventional aqueous injections have weak molecule-level patent protection and limited exclusivity.
3. The strongest commercial opportunities are ready-to-use bags, prefilled syringes, preservative-free products, and standardized emergency presentations.
4. Manufacturing quality, sterile capacity, packaging compatibility, and supply reliability are more important than composition-of-matter patents.
5. Paragraph IV litigation is less likely to be commercially important for basic magnesium sulfate injection than for branded products with dense Orange Book estates.
6. Formulation and device patents may protect differentiated products, but claims must be narrow, technically supported, and tied to measurable performance.
7. The best commercial model is a hospital electrolyte portfolio supported by reliable sterile manufacturing and institutional contracting.

Frequently Asked Questions

Is magnesium sulfate in water an excipient or an active ingredient?

It is normally the active ingredient. Water for Injection is the solvent, while other formulation components may function as pH adjusters, tonicity agents, or preservatives.

Can magnesium sulfate injection be sold over the counter?

Injectable magnesium sulfate is generally regulated as a prescription or hospital-administered product. Regulatory status varies by jurisdiction and route.

Is a ready-to-use magnesium sulfate bag patentable?

A ready-to-use bag may support patent protection if it has a novel formulation, container, stability profile, delivery system, or manufacturing process. The bag itself does not automatically create exclusivity.

What is the largest regulatory risk for a new magnesium sulfate injectable?

The largest risks are sterile manufacturing failure, incorrect concentration, particulate contamination, endotoxin exposure, container-closure defects, and inadequate stability data.

Is magnesium sulfate a good target for pharmaceutical licensing?

It is more attractive for licensing when combined with a differentiated delivery system, sterile manufacturing capability, shortage-response capacity, or hospital portfolio strategy. Conventional bulk magnesium sulfate has limited licensing value.

References

1. DailyMed. (2024a). Magnesium sulfate injection, solution: Prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. DailyMed. (2024b). Magnesium sulfate in water for injection: Prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugsatfda

4. U.S. Food and Drug Administration. (2024). Current good manufacturing practice for finished pharmaceuticals, 21 C.F.R. Parts 210 and 211. https://www.ecfr.gov/

5. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP-NF.